REVLIMID® (lenalidomide) in combination with a rituximab product is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL). REVLIMID in combination with a rituximab product is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

For patients with RRFL

Take Patients Further*

See Data

For patients with RRFL

Take Patients Further*

See Data

Dosing

Jacklyn Gideon, MSN, AGPCNP-BC, an Advanced Practice Nurse at the University of Chicago, talks about R2 dosing and the 12-cycle fixed-duration treatment of follicular lymphoma in the Phase III AUGMENT trial.

Watch the Video

Clinical Trial Data

In the pivotal Phase III AUGMENT trial, R2 was studied in a broad range of patients with previously treated FL or MZL. R2 showed a median progression-free survival of 39.4 months compared to 14.1 months with rituximab alone-that’s more than two times longer PFS.

Read more

Mechanism of Action

Dr. Joseph Tuscano, Professor of Medicine at UC Davis, explains how this immunotherapy combination has been shown to increase immune-mediated killing via ADCC and increase direct tumor apoptosis in FL and MZL cells in vitro.

Watch the Video

Based on in vitro data

R2 has been shown to work through complementary mechanisms.1

The combination of REVLIMID and rituximab increases ADCC and direct tumor apoptosis.1

AUGMENT clinical trial primary endpoint

Progression-free survival.2

Learn about REVLIMID + rituximab (R2).

NCCN Guidelines® Category 2A recommendation in Follicular Lymphoma.

Lenalidomide (REVLIMID) + rituximab is a preferred treatment option (Category 2A) recommended in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for second-line and subsequent therapy for patients with Grade 1-2 follicular lymphoma.3*

*See full NCCN Guidelines® for further details about recommended therapies.


ADCC, antibody-dependent cell-mediated cytotoxicity;
FL, follicular lymphoma;
MZL, marginal zone lymphoma; NCCN, National Comprehensive Cancer Network.

See full reference list.